Band 4
Band 4
About
Provided by Kirian Claeyé
Practice Areas
The newest Partner at ALTIUS, Kirian specialises in intellectual property and regulatory affairs relating to the pharmaceutical field.
His IP work focuses on complex patent litigation, often involving cross-border issues, parallel trade disputes, and support and advice regarding IP portfolio management. His regulatory work spans the fields of launch and marketing strategies, pricing and reimbursement, tendering, advertising, and lifecycle management.
Professional Memberships
Kirian is a member of the Boalt Hall Alumni Association, (Young) EPLAW, Licensing Executives Society, and the Belgian American Educational Foundation (BAEF).
Publications
• “Evoluties in het octrooirecht – Overzicht van rechtspraak 2018-2022”, TBH 2022, 435-489 (co-author)
• “Vrijwaring voor uitwinning en intellectuele eigendom” in B. Tilleman & B. Devolder, Weens Koopverdrag, Brugge, Die Keure, 2022, pp. 551-618 (co-author)
• “Pharmaceutical IP and Competition law in Belgium: Overview”, Thomson Reuters, 1 August 2021 (co-author)
• “Must AstraZeneca supply the EU with sufficient COVID-19 vaccines?”, ILO Healthcare & Life Sciences, 10 February 2021 / Mondaq, 13 April 2021
• “Belgium” in J. Bühling, Patent Protection for Second Medical Uses, The Netherlands, Kluwer, 2020 (co-author)
• The Pharma Legal Handbook: Belgium, PharmaBoardroom 2020 (co-author)
• “Evoluties in het octrooirecht – Overzicht van rechtspraak 2014-2018”, TBH-RDC 2018, 747-798 (co-author)
Additionally Kirian regularly speaks at conferences and seminars, is host of ALTIUS’ annual Pharma Law Seminar, and in charge of ALTIUS’ two-monthly Life Sciences Sessions.
Articles, highlights and press releases
3 items provided by ALTIUS
The 5 major changes in Belgian pharma law of 2023
Both the Belgian legislator and government have played an active role in 2023 when it comes to pharma legislation, which has led to a number of changes in the legal framework. In this article, we look back and discuss five noteworthy developments in Belgian pharma law.
Belgian Medicines Agency announces stricter monitoring of negative formulations on medicines packagi
On 17 May 2023, the Belgian Medicines Agency (FAMHP) announced that marketing authorisation holders (MAHs) have three years to comply with the prohibition of “negative formulations” on the packaging of medicinal products for human use.
CJEU interprets the concept of a global MA strictly
On 16 March 2023, in Joined Cases C‑438/21 P to C‑440/21 P, the Court of Justice of the European Union (CJEU) interpreted the concept of a ‘global marketing authorisation’.
The 5 major changes in Belgian pharma law of 2023
Both the Belgian legislator and government have played an active role in 2023 when it comes to pharma legislation, which has led to a number of changes in the legal framework. In this article, we look back and discuss five noteworthy developments in Belgian pharma law.
Belgian Medicines Agency announces stricter monitoring of negative formulations on medicines packagi
On 17 May 2023, the Belgian Medicines Agency (FAMHP) announced that marketing authorisation holders (MAHs) have three years to comply with the prohibition of “negative formulations” on the packaging of medicinal products for human use.
CJEU interprets the concept of a global MA strictly
On 16 March 2023, in Joined Cases C‑438/21 P to C‑440/21 P, the Court of Justice of the European Union (CJEU) interpreted the concept of a ‘global marketing authorisation’.
Discover other Lawyers at
ALTIUS
Belgium
